Axovant Gene Therapies Ltd (NASDAQ:AXGT) – Research analysts at Oppenheimer issued their FY2024 earnings per share estimates for shares of Axovant Gene Therapies in a report issued on Wednesday, June 12th. Oppenheimer analyst J. Olson forecasts that the company will post earnings per share of ($1.52) for the year.
A number of other research analysts have also recently commented on AXGT. Zacks Investment Research cut Axovant Gene Therapies from a “strong-buy” rating to a “hold” rating in a report on Friday, May 31st. ValuEngine cut Axovant Gene Therapies from a “buy” rating to a “hold” rating in a report on Friday, June 7th. Evercore ISI assumed coverage on Axovant Gene Therapies in a report on Thursday, April 11th. They issued an “outperform” rating on the stock. JMP Securities upped their price objective on Axovant Gene Therapies from $8.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, June 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $56.00 price objective on shares of Axovant Gene Therapies in a report on Tuesday, March 12th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $35.50.
Axovant Gene Therapies (NASDAQ:AXGT) last released its quarterly earnings data on Tuesday, June 11th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.70) by $1.25.
A number of large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new position in Axovant Gene Therapies during the first quarter worth $3,430,000. Jefferies Group LLC acquired a new position in Axovant Gene Therapies during the first quarter worth $3,354,000. Primecap Management Co. CA acquired a new position in Axovant Gene Therapies during the first quarter worth $1,400,000. Macquarie Group Ltd. acquired a new position in Axovant Gene Therapies during the first quarter worth $1,150,000. Finally, Morgan Stanley acquired a new position in Axovant Gene Therapies during the first quarter worth $291,000.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
See Also: Why Net Income is Important to Investors
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.